Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
16.45
-0.50 (-2.95%)
At close: Mar 9, 2026, 4:00 PM EDT
16.48
+0.03 (0.18%)
After-hours: Mar 9, 2026, 6:22 PM EDT
Tango Therapeutics Employees
Tango Therapeutics had 137 employees as of December 31, 2025. The number of employees decreased by 18 or -11.61% compared to the previous year.
Employees
137
Change (1Y)
-18
Growth (1Y)
-11.61%
Revenue / Employee
$455,358
Profits / Employee
-$741,562
Market Cap
2.35B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Apellis Pharmaceuticals | 739 |
| Adaptive Biotechnologies | 624 |
| Beam Therapeutics | 511 |
| Travere Therapeutics | 497 |
| Ocular Therapeutix | 325 |
| Wave Life Sciences | 317 |
| Dyne Therapeutics | 258 |
TNGX News
- 3 days ago - Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise - Seeking Alpha
- 7 weeks ago - Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - GlobeNewsWire
- 2 months ago - Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewsWire
- 2 months ago - Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy - Seeking Alpha
- 4 months ago - Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript - Seeking Alpha